+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Basal Insulin"

Type 1 Diabetes Market Report 2025 - Product Thumbnail Image

Type 1 Diabetes Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Human Insulin Market 2025-2033 - Product Thumbnail Image

Human Insulin Market 2025-2033

  • Report
  • March 2025
  • 145 Pages
  • Global
From
Diabetes - Pipeline Insight, 2024 - Product Thumbnail Image

Diabetes - Pipeline Insight, 2024

  • Clinical Trials
  • November 2024
  • 450 Pages
  • Global
From
From
human insulin market - Forecasts from 2025 to 2030 - Product Thumbnail Image

human insulin market - Forecasts from 2025 to 2030

  • Report
  • December 2024
  • 144 Pages
  • Global
From
Type 2 Diabetes - Pipeline Insight, 2024 - Product Thumbnail Image

Type 2 Diabetes - Pipeline Insight, 2024

  • Drug Pipelines
  • November 2024
  • 240 Pages
  • Global
From
Insulin Patch Pumps Market - Product Thumbnail Image

Insulin Patch Pumps Market

  • Report
  • May 2024
  • 200 Pages
  • Global
From
From
From
LEVEMIR Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

LEVEMIR Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
Insulin Glargine- - Biosimilar Insight, 2022 - Product Thumbnail Image

Insulin Glargine- - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
From
From
From
From
From
Loading Indicator

Within the field of endocrinology and metabolic disorders drugs, the basal insulin market is a prominent segment addressing the therapeutic needs of patients with diabetes mellitus, primarily type 1 diabetes and advanced type 2 diabetes. Basal insulin preparations are designed to be long-acting, maintaining consistent insulin levels in the bloodstream to control blood glucose throughout the day and night. These insulins aim to mimic the insulin secretion of a healthy pancreas and are typically administered once or twice daily. The treatment paradigm for diabetes has evolved to prioritize individual patient needs, and within this context, basal insulins offer different profiles in terms of onset of action, peak activity, and duration of effect. Technological advancements have led to newer insulin analogs and delivery systems that seek to improve glycemic control and reduce the risk of hypoglycemia. Key challenges in the market include the management of therapy costs and ensuring accessibility to these life-sustaining drugs. Prominent participants in the basal insulin market include Sanofi with its Lantus and Toujeo lines, Novo Nordisk offering Levemir and Tresiba, and Eli Lilly with the Basaglar and Humulin product families. These companies compete not only on efficacy and safety but also in areas such as pricing, delivery mechanisms, and patient support programs. Show Less Read more